Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Parkinson's disease

Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,412 · see citing works

Neuroinflammation in Alzheimer's disease

Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · see citing works

The amyloid hypothesis of Alzheimer's disease at 25 years

Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · see citing works

Drug repurposing: progress, challenges and recommendations

Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718 · see citing works

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes

Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116 · see citing works

Parkinson's disease

Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920 · see citing works

The neuropathological diagnosis of Alzheimer's disease

DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · see citing works

Applications of machine learning in drug discovery and development

Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228 · see citing works

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · see citing works

Diagnosis and Treatment of Parkinson Disease: A Review

Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924 · see citing works

Biological Functions of Autophagy Genes: A Disease Perspective

Levine, B., & Kroemer, G. (2019) · Cell · doi:10.1016/j.cell.2018.09.048 · Cited by 2,832 · see citing works

Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609 · see citing works

Alzheimer disease

Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606 · see citing works

The role of autophagy in neurodegenerative disease

Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059 · see citing works

The pathways of mitophagy for quality control and clearance of mitochondria

Ashrafi, G., & Schwarz, T. L. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.81 · Cited by 1,900 · see citing works

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879 · see citing works

Huntington's disease: from molecular pathogenesis to clinical treatment

Ross, C. A., & Tabrizi, S. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,751 · see citing works

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,735 · see citing works

Autophagy and autophagy-related proteins in cancer

Li, X., He, S., & Ma, B. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1138-4 · Cited by 1,653 · see citing works

Autophagy: molecular machinery for self-eating

Yorimitsu, T., & Klionsky, D. J. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401765 · Cited by 1,540 · see citing works

Autophagy pathway: Cellular and molecular mechanisms

Yu, L., Chen, Y., & Tooze, S. A. (2017) · Autophagy · doi:10.1080/15548627.2017.1378838 · Cited by 1,488 · see citing works

Induced protein degradation: an emerging drug discovery paradigm

Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486 · see citing works

Lysosomes as dynamic regulators of cell and organismal homeostasis

Ballabio, A., & Bonifacino, J. S. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0185-4 · Cited by 1,469 · see citing works

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

Bennett, C. F., & Swayze, E. E. (2010) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,381 · see citing works

Targeted drug delivery strategies for precision medicines

Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N. X., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,201 · see citing works

Lysosome-targeting chimaeras for degradation of extracellular proteins

Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199 · see citing works

Autophagy in Human Diseases

Mizushima, N., & Levine, B. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2022774 · Cited by 1,140 · see citing works

Kinase drug discovery 20 years after imatinib: progress and future directions

Cohen, P., Cross, D. A. E., & Janne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,066 · see citing works

Mechanisms of Deubiquitinase Specificity and Regulation

Mevissen, T. E. T., & Komander, D. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044916 · Cited by 1,035 · see citing works

Huntington disease: natural history, biomarkers and prospects for therapeutics

Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016 · see citing works

Roles of tau protein in health and disease

Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003 · see citing works

Targeted protein degradation: mechanisms, strategies and application

Zhao, L., Zhao, J., Zhong, K., Tong, A., & Jia, D. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00966-4 · Cited by 986 · see citing works

Targeting Autophagy in Cancer: Recent Advances and Future Directions

Amaravadi, R. K., Kimmelman, A. C., & Debnath, J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0292 · Cited by 928 · see citing works

Drugging the ‘undruggable’ cancer targets

Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927 · see citing works

Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies

Ciechanover, A., & Kwon, Y. T. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.117 · Cited by 898 · see citing works

PROTACs: past, present and future

Li, K., & Crews, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00193d · Cited by 869 · see citing works

The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy

Bingol, B., Tea, J. S., Phu, L., Reichelt, M., Bakalarski, C. E., Song, Q., Foreman, O., Kirkpatrick, D. S., & Sheng, M. (2014) · Nature · doi:10.1038/nature13418 · Cited by 855 · see citing works

Breaking the chains: deubiquitylating enzyme specificity begets function

Clague, M. J., Urbé, S., & Komander, D. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0099-1 · Cited by 839 · see citing works

Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis

Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770 · see citing works

BRD4 and Cancer: going beyond transcriptional regulation

Donati, B., Lorenzini, E., & Ciarrocchi, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0915-9 · Cited by 724 · see citing works

Lipid droplets and liver disease: from basic biology to clinical implications

Gluchowski, N. L., Becuwe, M., Walther, T. C., & Farese, R. V. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.32 · Cited by 675 · see citing works

AUTACs: Cargo-Specific Degraders Using Selective Autophagy

Takahashi, D., Moriyama, J., Nakamura, T., Miki, E., Takahashi, E., Sato, A., Akaike, T., Itto-Nakama, K., & Arimoto, H. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.009 · Cited by 675 · see citing works

Advancing targeted protein degradation for cancer therapy

Dale, B., Cheng, M., Park, K., Kanıskan, H. Ü., Xiong, Y., & Jin, J. J. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00365-x · Cited by 671 · see citing works

Strategic Approaches to Optimizing Peptide ADME Properties

Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669 · see citing works

Alzheimer’s disease drug development pipeline: 2022

Cummings, J., Lee, G., Nahed, P., Kambar, M. E. Z. N., Zhong, K., Fonseca, J., & Taghva, K. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12295 · Cited by 665 · see citing works

PROTACs: great opportunities for academia and industry

Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y.-G., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 651 · see citing works

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres‐Lockhart, K., Prat, A., Antón, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 609 · see citing works

Targeted protein degradation: elements of PROTAC design

Paiva, S.-L., & Crews, C. M. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.022 · Cited by 586 · see citing works

Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds

Li, Z., Wang, C., Wang, Z., Zhu, C., Li, J., Sha, T., Ma, L., Gao, C., Yang, Y., Sun, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1722-1 · Cited by 551 · see citing works

Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1

Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B., & Wells, J. A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10008 · Cited by 551 · see citing works

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Li, X., & Song, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00885-3 · Cited by 550 · see citing works

Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities

Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 544 · see citing works

PROTACs: An Emerging Therapeutic Modality in Precision Medicine

Nalawansha, D. A., & Crews, C. M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 514 · see citing works

Regulation of intestinal lipid metabolism: current concepts and relevance to disease

Ko, C.-W., Qu, J., Black, D. D., & Tso, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0250-7 · Cited by 510 · see citing works

Development of targeted protein degradation therapeutics

Chamberlain, P. P., & Hamann, L. G. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0362-y · Cited by 489 · see citing works

Interactions of pathological proteins in neurodegenerative diseases

Spires‐Jones, T. L., Attems, J., & Thal, D. R. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1709-7 · Cited by 424 · see citing works

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Cromm, P. M., & Crews, C. M. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.05.024 · Cited by 423 · see citing works

Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy

Zhang, C., Zeng, Z., Cui, D. M., He, S., Jiang, Y., Li, J., Huang, J., & Pu, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23194-w · Cited by 417 · see citing works

Autophagy in tumour immunity and therapy

Xia, H., Green, D. R., & Zou, W. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00344-2 · Cited by 411 · see citing works

Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules

Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409 · see citing works

Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: One in the presence and one in the absence of CsA

Friedman, J. S., & Weissman, I. L. (1991) · Cell · doi:10.1016/0092-8674(91)90123-g · Cited by 396 · see citing works

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01434-3 · Cited by 374 · see citing works

Autophagy and disease: unanswered questions

Yang, Y., & Klionsky, D. J. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-019-0480-9 · Cited by 369 · see citing works

Selective autophagy as a potential therapeutic target for neurodegenerative disorders

Scrivo, A., Bourdenx, M., Pampliega, O., & Cuervo, A. M. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30238-2 · Cited by 355 · see citing works

The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system

Ji, C. H., Kim, H. Y., Lee, M. J., Heo, A. J., Park, D. Y., Lim, S., Shin, S., Ganipisetti, S., Yang, W. S., Jung, C. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28520-4 · Cited by 350 · see citing works

Autophagy and Autophagy-Related Diseases: A Review

Ichimiya, T., Yamakawa, T., Hirano, T., Yokoyama, Y., Hayashi, Y., Hirayama, D., Wagatsuma, K., Itoi, T., & Nakase, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238974 · Cited by 338 · see citing works

PHOTACs enable optical control of protein degradation

Reynders, M., Matsuura, B. S., Bérouti, M., Simoneschi, D., Marzio, A., Pagano, M., & Trauner, D. H. (2020) · Science Advances · doi:10.1126/sciadv.aay5064 · Cited by 333 · see citing works

Huntingtin Lowering Strategies for Disease Modification in Huntington’s Disease

Tabrizi, S. J., Ghosh, R., & Leavitt, B. R. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.039 · Cited by 330 · see citing works

USP30 and parkin homeostatically regulate atypical ubiquitin chains on mitochondria

Cunningham, C. N., Baughman, J. M., Phu, L., Tea, J. S., Yu, C., Coons, M. M., Kirkpatrick, D. S., Bingol, B., & Corn, J. E. (2015) · Nature Cell Biology · doi:10.1038/ncb3097 · Cited by 329 · see citing works

Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation

Chen, Y., Tandon, I., Heelan, W. J., Wang, Y., Tang, W., & Hu, Q. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00762a · Cited by 327 · see citing works

Target and tissue selectivity of PROTAC degraders

Guenette, R. G., Yang, S. W., Min, J., Pei, B., & Potts, P. R. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00200k · Cited by 324 · see citing works

The future of stem cell therapies for Parkinson disease

Parmar, M., Grealish, S., & Henchcliffe, C. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0257-7 · Cited by 314 · see citing works

Chemistries of bifunctional PROTAC degraders

Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313 · see citing works

Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy

Hu, Q., Sun, W., Wang, J., Ruan, H., Zhang, X., Ye, Y., Shen, S., Wang, C., Lu, W., Cheng, K., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0310-2 · Cited by 311 · see citing works

Light-induced control of protein destruction by opto-PROTAC

Liu, J., Chen, H., Ma, L., He, Z., Wang, D., Liu, Y., Lin, Q., Zhang, T., Gray, N. S., Kanıskan, H. Ü., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay5154 · Cited by 305 · see citing works

Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment

Lombardo, S., & Maskos, U. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.018 · Cited by 303 · see citing works

Targeting the lysosome in cancer

Piao, S., & Amaravadi, R. K. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12953 · Cited by 303 · see citing works

Therapies targeting DNA and RNA in Huntington's disease

Wild, E. J., & Tabrizi, S. J. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30280-6 · Cited by 299 · see citing works

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Qi, S., Dong, J., Xu, Z., Cheng, X., Zhang, W., & Qin, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.692574 · Cited by 299 · see citing works

Targeted protein degradation: A promise for undruggable proteins

Samarasinghe, K. T. G., & Crews, C. M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.011 · Cited by 291 · see citing works

The PROTACtable genome

Schneider, M., Radoux, C. J., Hercules, A., Ochoa, D., Dunham, I., Zalmas, L.-P., Hessler, G., Ruf, S., Shanmugasundaram, V., Hann, M. M., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00245-x · Cited by 273 · see citing works

The Atg1 Kinase Complex Is Involved in the Regulation of Protein Recruitment to Initiate Sequestering Vesicle Formation for Nonspecific Autophagy inSaccharomyces cerevisiae

Cheong, H., Nair, U., Geng, J., & Klionsky, D. J. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-08-0826 · Cited by 262 · see citing works

Shaping proteostasis at the cellular, tissue, and organismal level

Sala, A. J., Bott, L. C., & Morimoto, R. I. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201612111 · Cited by 246 · see citing works

Bifunctional small molecules that mediate the degradation of extracellular proteins

Caianiello, D. F., Zhang, M., Ray, J. D., Howell, R. A., Swartzel, J. C., Branham, E. M. J., Chirkin, E., Sabbasani, V. R., Gong, A. Z., McDonald, D. M., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00851-1 · Cited by 244 · see citing works

Autophagy Induction as a Therapeutic Strategy for Neurodegenerative Diseases

Djajadikerta, A., Keshri, S., Tanasa, M. P., Prestil, R., Ryan, L., & Rubinsztein, D. C. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.12.035 · Cited by 238 · see citing works

Degradation of lipid droplets by chimeric autophagy-tethering compounds

Fu, Y., Chen, N., Wang, Z., Luo, S., Ding, Y., & Lu, B. (2021) · Cell Research · doi:10.1038/s41422-021-00532-7 · Cited by 232 · see citing works

Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy

Gao, J., Hou, B., Zhu, Q., Yang, L., Jiang, X., Zou, Z., Li, X., Xu, T., Zheng, M., Chen, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32050-4 · Cited by 226 · see citing works

ATTEC: a potential new approach to target proteinopathies

Li, Z., Zhu, C., Ding, Y., Fei, Y., & Lu, B. (2019) · Autophagy · doi:10.1080/15548627.2019.1688556 · Cited by 214 · see citing works

Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update

Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106037 · Cited by 208 · see citing works

Emerging New Concepts of Degrader Technologies

Ding, Y., Fei, Y., & Lu, B. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.005 · Cited by 204 · see citing works

Pyridoxine induces glutathione synthesis via PKM2-mediated Nrf2 transactivation and confers neuroprotection

Yao, W., Lu, M., Mei, M., Wang, H., Han, Z., Chen, M., Yao, H. P., Song, N., Ding, X. L., Ding, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14788-x · Cited by 196 · see citing works

Gene-based therapies for neurodegenerative diseases

Sun, J., & Roy, S. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00778-1 · Cited by 189 · see citing works

Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown

Jin, Y., Lu, M., Wang, Y., Shan, W.-X., Wang, X.-Y., You, Q., & Jiang, Z. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02058 · Cited by 188 · see citing works

NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP

Lucena-Cacace, A., Otero-Albiol, D., Jiménez-García, M. P., Muñoz-Galván, S., & Carnero, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2575 · Cited by 166 · see citing works

Emerging degrader technologies engaging lysosomal pathways

Ding, Y., Xing, D., Fei, Y., & Lu, B. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00624c · Cited by 162 · see citing works

Degrader-antibody conjugates

Dragovich, P. S. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00141a · Cited by 161 · see citing works

Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial

Volc, D., Poewe, W. H., Kutzelnigg, A., Lührs, P., Thun-Hohenstein, C., Schneeberger, A., Galabova, G., Majbour, N. K., Vaikath, N. N., El‐Agnaf, O. M. A., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30136-8 · Cited by 160 · see citing works

Discovery of Small Molecules that Induce the Degradation of Huntingtin

Tomoshige, S., Nomura, S., Ohgane, K., Hashimoto, Y., & Ishikawa, M. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201706529 · Cited by 144 · see citing works

The state of the art of PROTAC technologies for drug discovery

Wang, C., Zheng, C., Wang, H., Zhang, L., Liu, Z., & Xu, P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114290 · Cited by 129 · see citing works

Autophagy-modulating phytochemicals in cancer therapeutics: Current evidences and future perspectives

Patra, S., Mishra, S. R., Behera, B. P., Mahapatra, K. K., Panigrahi, D. P., Bhol, C. S., Praharaj, P. P., Sethi, G., Patra, S. K., & Bhutia, S. K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.008 · Cited by 126 · see citing works

Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery

Pei, J., Wang, G., Feng, L., Zhang, J., Jiang, T., Sun, Q., & Ouyang, L. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01689 · Cited by 124 · see citing works

An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion

Keller, C. G., Shin, Y., Monteys, A. M., Renaud, N., Beibel, M., Teider, N., Peters, T., Faller, T., St-Cyr, S., Knehr, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28653-6 · Cited by 123 · see citing works

Mitochondrial dynamics and quality control in Huntington's disease

Guedes-Dias, P., Pinho, B. R., Soares, T. R., de Proença, J., Duchen, M. R., & Oliveira, J. M. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.09.008 · Cited by 119 · see citing works

Dopamine restores cognitive motivation in Parkinson’s disease

McGuigan, S., Zhou, S.-H., Brosnan, M. B., Thyagarajan, D. E., Bellgrove, M. A., & Chong, T. T. ‐. (2018) · Brain · doi:10.1093/brain/awy341 · Cited by 106 · see citing works

siRNA screen identifies QPCT as a druggable target for Huntington's disease

Jiménez-Sánchez, M., Lam, W., Hannus, M., Sönnichsen, B., Imarisio, S., Fleming, A., Tarditi, A., Menzies, F. M., Dami, T. E., Xu, C. K., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1790 · Cited by 102 · see citing works

Identification of NUB1 as a suppressor of mutant Huntingtin toxicity via enhanced protein clearance

Lu, B., Al‐Ramahi, I., Valencia, A., Wang, Q., Berenshteyn, F., Yang, H., Gallego‐Flores, T., Ichcho, S., Lacoste, A., Hild, M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3367 · Cited by 99 · see citing works

PROTAC degraders as chemical probes for studying target biology and target validation

Němec, V., Schwalm, M. P., Müller, S., & Knapp, S. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00478j · Cited by 98 · see citing works

Targeting selective autophagy by AUTAC degraders

Takahashi, D., & Arimoto, H. (2020) · Autophagy · doi:10.1080/15548627.2020.1718362 · Cited by 96 · see citing works

Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy

Pei, J., Pan, X., Wang, A., Wen, S., Bu, F., Tang, P., Zhang, S., Zhang, Y., Wang, G., & Ouyang, L. (2021) · Chemical Communications · doi:10.1039/d1cc04661f · Cited by 96 · see citing works

Ispinesib as an Effective Warhead for the Design of Autophagosome-Tethering Chimeras: Discovery of Potent Degraders of Nicotinamide Phosphoribosyltransferase (NAMPT)

Dong, G., Wu, Y., Cheng, J., Chen, L., Liu, R., Ding, Y., Wu, S., Ma, J., & Sheng, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02001 · Cited by 95 · see citing works

Recent Advances in PROTACs for Drug Targeted Protein Research

Yao, T., Xiao, H., Wang, H., & Xu, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810328 · Cited by 78 · see citing works

Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work

Kumar, R., Harilal, S., Gupta, S. V., Jose, J., Parambi, D. G. T., Uddin, M. S., Shah, M. A., & Mathew, B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111602 · Cited by 75 · see citing works

Autophagy receptors in developmental clearance of mitochondria

Novak, I., & Đikić, I. (2011) · Autophagy · doi:10.4161/auto.7.3.14509 · Cited by 74 · see citing works

The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis

Drumond‐Bock, A. L., & Bieniasz, M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01424-5 · Cited by 70 · see citing works

Protacs for Treatment of Cancer

Sakamoto, K. M. (2010) · Pediatric Research · doi:10.1203/pdr.0b013e3181d35017 · Cited by 63 · see citing works

Targeting Gpr52 lowers mutant HTT levels and rescues Huntington’s disease-associated phenotypes

Song, H., Li, H., Guo, S., Pan, Y., Fu, Y., Zhou, Z., Li, Z., Wen, X., Sun, X., He, B., et al. (2018) · Brain · doi:10.1093/brain/awy081 · Cited by 62 · see citing works

Mitophagy Regulates Neurodegenerative Diseases

Cen, X., Zhang, M., Zhou, M., Ye, L., & Xia, H. (2021) · Cells · doi:10.3390/cells10081876 · Cited by 58 · see citing works

Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting Chimera)

Ji, C. H., Lee, M. J., Kim, H. Y., et al. (2022) · Autophagy · doi:10.1080/15548627.2022.2091338 · Cited by 57 · see citing works

Degradation of huntingtin mediated by a hybrid molecule composed of IAP antagonist linked to phenyldiazenyl benzothiazole derivative

Tomoshige, S., Nomura, S., Ohgane, K., Hashimoto, Y., & Ishikawa, M. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.01.012 · Cited by 55 · see citing works

Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis

Onur, T. S., Laitman, A., He, Z., Keyho, R., Kim, H. M., Wang, J. P., Mair, M. L., Wang, H., Li, L., Perez, A. M., et al. (2021) · eLife · doi:10.7554/elife.64564 · Cited by 55 · see citing works

Identification of an autoinhibitory, mitophagy-inducing peptide derived from the transmembrane domain of USP30

Qin, X., Wang, R., Xu, H., Tu, L., Chen, H., Li, H., Liu, N., Wang, J., Li, S., Yin, F., et al. (2022) · Autophagy · doi:10.1080/15548627.2021.2022360 · Cited by 55 · see citing works

PROTAC technology for the treatment of Alzheimer’s disease: advances and perspectives

Inuzuka, H., Liu, J., Wei, W., & Rezaeian, A.-H. (2022) · Acta Materia Medica · doi:10.15212/amm-2021-0001 · Cited by 51 · see citing works

USP30: Structure, Emerging Physiological Role, and Target Inhibition

Wang, F., Gao, Y. P., Zhou, L., Chen, J., Xie, Z., Ye, Z., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.851654 · Cited by 51 · see citing works

Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington's disease models

Yu, M., Fu, Y., Liang, Y., Song, H., Yao, Y., Wu, P., Yao, Y., Pan, Y., Wen, X., Ma, L., et al. (2017) · Cell Research · doi:10.1038/cr.2017.113 · Cited by 39 · see citing works

Conformation Polymorphism of Polyglutamine Proteins

Feng, X., Luo, S., & Lu, B. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.03.002 · Cited by 34 · see citing works

HIPK3 modulates autophagy and HTT protein levels in neuronal and mouse models of Huntington disease

Fu, Y., Sun, X., & Lu, B. (2017) · Autophagy · doi:10.1080/15548627.2017.1393130 · Cited by 23 · see citing works

Targeted protein degradation using the lysosomal pathway

Ghosh, S., Ramadas, B., & Manna, D. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00273f · Cited by 21 · see citing works

The Immune System as a Therapeutic Target for Alzheimer’s Disease

Zieneldien, T., Kim, J., Sawmiller, D. R., & Cao, C. (2022) · Life · doi:10.3390/life12091440 · Cited by 19 · see citing works

Methionine Aminopeptidase 2 as a Potential Therapeutic Target for Human Non-Small-Cell Lung Cancers

Shimizu, H., Yamagishi, S., Chiba, H., & Ghazizadeh, M. (2015) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/60715 · Cited by 18 · see citing works

Suppression of glioblastoma growth and angiogenesis through molecular targeting of methionine aminopeptidase-2

Lin, M., Zhang, X., Jia, B., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2663-x · Cited by 17 · see citing works

Deciphering the Rules of in Silico Autophagy Methods for Expediting Medicinal Research

Chen, Y., Wang, G., Cai, H., Sun, Y., Ouyang, L., & Liu, B. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01673 · Cited by 10 · see citing works

The dual face of NAMPT: Intracellular/extracellular protein and diagnostic/therapeutic target in cancer

Audrito, V. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103109 · Cited by 10 · see citing works

Recent Advancements in the Discovery of Cereblon-Based Protease-Targeted Chimeras With Potential for Therapeutic Intervention

Singh, H., & Agrawal, D. K. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0149 · Cited by 10 · see citing works

Autophagy : molecules and mechanisms

Lane, J. D. (2013) · Portland Press eBooks · Cited by 5 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Autophagy Flux: A Bottleneck in the Clearance of Damaged Organelles and Proteins after Skeletal Muscle Injury

Nichenko, A. S., Tehrani, K. F., Yin, A., et al. (2020) · The FASEB Journal · doi:10.1096/fasebj.2020.34.s1.05440 · Cited by 3 · see citing works

Introduction to Autophagy

Hayat, M. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-405530-8.00001-7

Autophagic Flux Assessment in Colorectal Cancer Cells

Lauzier, A., & Jean, S. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7765-9_10 · Cited by 3 · see citing works

Introduction to Autophagy

Hayat, M. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-405877-4.00001-9 · Cited by 1 · see citing works

Introduction to Autophagy

Hayat, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405529-2.00001-9 · Cited by 1 · see citing works